.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC18_Risankizumab.Risankizumab

Information

Risankizumab is a humanized immunoglobulin G1 monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23). It is used for the treatment of moderate to severe plaque psoriasis, and is approved for this indication in several regions including the US and EU.

Pharmacokinetics

Pharmacokinetic parameters reported for adult patients with moderate to severe plaque psoriasis after subcutaneous administration.

References

1. Thakre, N, et al., & Pang, Y (2024). Population Pharmacokinetic and Exposure-Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis. Clinical pharmacology and therapeutics 116(3) 847–857. DOI:10.1002/cpt.3330 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38863178

2. Thakre, N, et al., & Suleiman, AA (2022). Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatology and therapy 9(6) 1587–1603. DOI:10.1007/s40744-022-00495-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36178584

3. Pang, Y, et al., & Othman, AA (2020). Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients. Clinical pharmacokinetics 59(3) 311–326. DOI:10.1007/s40262-019-00842-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31758502

Revisions

• 06/2025 initial generated model